The PARADIGM-HF study involving heart failure patients with systolic dysfunction showed that the combination of neprilysin inhibition by sacubitril and the AT1R blocker valsartan, i.e., sacubitril/valsartan (ARNI), reduced morbidity and mortality more effectively than the ACE inhibitor enalapril [6]. This evidence concerns the gene ACE and hydrops fetalis.